InvestorsHub Logo
Followers 250
Posts 14020
Boards Moderated 3
Alias Born 07/07/2006

Re: wjlknew post# 5108

Tuesday, 05/22/2007 1:50:08 PM

Tuesday, May 22, 2007 1:50:08 PM

Post# of 6489
Buyout 50% premium is normal for established companies with regular revenue, not for promising biotech
Its all about potential revenue vs market cap.

a buyout at 50%+ from current levelslevels would never work at this moment for a promising biotech such as insm,

better example is RNAI there
first climb from 2,50$ to 5,00$, than a 13$ takeover bid
http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=OBR&Date=20061030&ID=6149....
just one example

Very strongly disagree with wklnew there
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INSM News